文献速递围术期管理与 ERAS

前哨淋巴结活检在黑色素瘤中的治疗价值:一项随机临床试验

Therapeutic Value of Sentinel Lymph Node Biopsy in Patients With Melanoma: A Randomized Clinical Trial.
PubMed 文献 · JAMA Surg · 2022-01-01

MSLT-II试验纳入823例前哨淋巴结(SLN)阳性黑色素瘤患者,随机接受完成性淋巴结清扫(CLND)或淋巴结观察。本分析聚焦观察组,发现10年时80.2%的淋巴结 basin 无复发;无CLND的SLN活检在多数患者中可实现长期区域控制。

要点

  • SLN阳性黑色素瘤患者仅观察,10年80.2% basin 无复发。
  • 年轻、原发灶薄、腋窝、SLN负荷小与更低复发风险相关。
  • SLN活检除分期外,可能对部分患者有治疗价值。

核心结论

  • SLN活检不伴CLND在多数SLN阳性黑色素瘤患者中可实现长期区域淋巴结控制,可能具有治疗价值。

研究设计与样本

  • MSLT-II为前瞻性多中心随机临床试验,本分析纳入观察组823例SLN阳性黑色素瘤患者(18-75岁),共855个观察basin。

主要发现

  • 10年时80.2%(95%CI 77-83)的basin无淋巴结复发。
  • 多变量分析中,年轻年龄(HR 0.57;95%CI 0.39-0.84;P=.004)、较薄原发灶(HR 0.40;95%CI 0.22-0.70;P=.002)、腋窝basin(HR 0.55;95%CI 0.31-0.96;P=.03)、SLN转移直径<1 mm(HR 0.52;95%CI 0.33-0.81;P=.007)及面积<5%(HR 0.58;95%CI 0.38-0.88;P=.01)与basin控制相关。

关键数值与推荐

  • 5年basin无病率按风险因素数目:0个为96%(95%CI 88-100),1个为89%(95%CI 82-96),2个为86%(95%CI 80-93),3个为80%(95%CI 71-89),4个为61%(95%CI 48-74),5或6个为54%(95%CI 36-72)。
  • 风险因素包括年龄≥50岁、溃疡、Breslow厚度>3.5 mm、非腋窝basin、肿瘤负荷最大直径≥1 mm和/或转移面积≥5%。

临床怎么用

  • SLN阳性黑色素瘤患者可考虑仅行SLN活检加超声观察,避免常规CLND。
  • 可根据风险因素数目评估区域复发风险,指导随访强度。

局限性

  • 本分析仅针对观察组,未直接比较CLND与观察的长期区域控制差异。
  • 部分病例存在缺失值,风险因素分层分析排除了缺失值病例。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Sentinel lymph node (SLN) biopsy is a standard staging procedure for cutaneous melanoma. Regional disease control is a clinically important therapeutic goal of surgical intervention, including nodal surgery. OBJECTIVE: To determine how frequently SLN biopsy without completion lymph node dissection (CLND) results in long-term regional nodal disease control in patients with SLN metastases. DESIGN, SETTING, AND PARTICIPANTS: The second Multicenter Selective Lymphadenectomy Trial (MSLT-II), a prospective multicenter randomized clinical trial, randomized participants with SLN metastases to either CLND or nodal observation. The current analysis examines observation patients with regard to regional nodal recurrence. Trial patients were aged 18 to 75 years with melanoma metastatic to SLN(s). Data were collected from December 2004 to April 2019, and data were analyzed from July 2020 to January 2022. INTERVENTIONS: Nodal observation with ultrasonography rather than CLND. MAIN OUTCOMES AND MEASURES: In-basin nodal recurrence. RESULTS: Of 823 included patients, 479 (58.2%) were male, and the mean (SD) age was 52.8 (13.8) years. Among 855 observed basins, at 10 years, 80.2% (actuarial; 95% CI, 77-83) of basins were free of nodal recurrence. By univariable analysis, freedom from regional nodal recurrence was associated with age younger than 50 years (hazard ratio [HR], 0.49; 95% CI, 0.34-0.70; P < .001), nonulcerated melanoma (HR, 0.36; 95% CI, 0.36-0.49; P < .001), thinner primary melanoma (less than 1.5 mm; HR, 0.46; 95% CI, 0.27-0.78; P = .004), axillary basin (HR, 0.61; 95% CI, 0.44-0.86; P = .005), fewer positive SLNs (1 vs 3 or more; HR, 0.32; 95% CI, 0.14-0.75; P = .008), and SLN tumor burden (measured by diameter less than 1 mm [HR, 0.39; 95% CI, 0.26-0.60; P = .001] or less than 5% area [HR, 0.36; 95% CI, 0.24-0.54; P < .001]). By multivariable analysis, younger age (HR, 0.57; 95% CI, 0.39-0.84; P = .004), thinner primary melanoma (HR, 0.40; 95% CI, 0.22-0.70; P = .002), axillary basin (HR, 0.55; 95% CI, 0.31-0.96; P = .03), SLN metastasis diameter less than 1 mm (HR, 0.52; 95% CI, 0.33-0.81; P = .007), and area less than 5% (HR, 0.58; 95% CI, 0.38-0.88; P = .01) were associated with basin control. When looking at the identified risk factors of age (50 years or older), ulceration, Breslow thickness greater than 3.5 mm, nonaxillary basin, and tumor burden of maximum diameter of 1 mm or greater and/or metastasis area of 5% or greater and excluding missing value cases, basin disease-free rates at 5 years were 96% (95% CI, 88-100) for patients with 0 risk factors, 89% (95% CI, 82-96) for 1 risk factor, 86% (95% CI, 80-93) for 2 risk factors, 80% (95% CI, 71-89) for 3 risk factors, 61% (95% CI, 48-74) for 4 risk factors, and 54% (95% CI, 36-72) for 5 or 6 risk factors. CONCLUSIONS AND RELEVANCE: This randomized clinical trial was the largest prospective evaluation of long-term regional basin control in patients with melanoma who had nodal observation after removal of a positive SLN. SLN biopsy without CLND cleared disease in the affected nodal basin in most patients, even those with multiple risk factors for in-basin recurrence. In addition to its well-validated value in staging, SLN biopsy may also be regarded as therapeutic in some patients. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT00297895.

来源:JAMA Surg,查看原文。版权归原作者所有。

引用

  1. Crystal JS, Thompson JF, Hyngstrom J, et al. Therapeutic Value of Sentinel Lymph Node Biopsy in Patients With Melanoma: A Randomized Clinical Trial. JAMA Surg. 2022. PMID: 35921122. doi:10.1001/jamasurg.2022.2055

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。